Public Equities L.P. Invus Sells 363,949 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) Stock

GlycoMimetics, Inc. (NASDAQ:GLYC) major shareholder Public Equities L.P. Invus sold 363,949 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $0.24, for a total transaction of $87,347.76. Following the completion of the transaction, the insider now directly owns 7,966,780 shares in the company, valued at approximately $1,912,027.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Public Equities L.P. Invus also recently made the following trade(s):

• On Friday, July 26th, Public Equities L.P. Invus sold 258,335 shares of GlycoMimetics stock. The stock was sold at an average price of $0.24, for a total transaction of $62,000.40.

GlycoMimetics Stock Performance

Shares of NASDAQ GLYC traded down $0.02 during midday trading on Tuesday, hitting $0.22. The company’s stock had a trading volume of 4,611,246 shares, compared to its average volume of 2,260,446. GlycoMimetics, Inc. has a 1-year low of $0.20 and a 1-year high of $3.53. The firm’s fifty day moving average price is $0.28 and its 200-day moving average price is $1.69. The firm has a market cap of $14.05 million, a P/E ratio of -0.40 and a beta of 2.19.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). As a group, research analysts predict that GlycoMimetics, Inc. will post -0.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GLYC has been the topic of several analyst reports. StockNews.com assumed coverage on shares of GlycoMimetics in a research note on Thursday, July 25th. They set a “sell” rating on the stock. Capital One Financial lowered shares of GlycoMimetics from an “overweight” rating to an “equal weight” rating in a report on Monday, May 6th. TD Cowen lowered shares of GlycoMimetics from a “buy” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright reissued a “neutral” rating on shares of GlycoMimetics in a report on Tuesday, June 4th.

Institutional Trading of GlycoMimetics

An institutional investor recently bought a new position in GlycoMimetics stock. Advisor OS LLC acquired a new stake in GlycoMimetics, Inc. (NASDAQ:GLYC) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 101,000 shares of the biotechnology company’s stock, valued at approximately $238,000. Advisor OS LLC owned about 0.16% of GlycoMimetics as of its most recent SEC filing. Hedge funds and other institutional investors own 75.19% of the company’s stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.